

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

ENZO BIOCHEM INC  
Form 8-K  
December 11, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): DECEMBER 11, 2006

ENZO BIOCHEM, INC.

(Exact Name of Registrant as Specified in Its Charter)

NEW YORK

(State or Other Jurisdiction of Incorporation)

001-09974

13-2866202

(Commission File Number)

(IRS Employer Identification No.)

527 MADISON AVENUE  
NEW YORK, NEW YORK

10022

(Address of Principal Executive Offices)

(Zip Code)

(212) 583-0100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: ENZO BIOCHEM INC - Form 8-K

### ITEM 2.02. RESULTS OF OPERATION AND FINANCIAL CONDITION.

(a) The following information, including the Exhibit attached hereto, is being furnished pursuant to this Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On December 11, 2006, Enzo Biochem, Inc., a New York corporation (the "Company"), issued a press release discussing its financial results for its fiscal quarter ended October 31, 2006. A copy of the press release is furnished as Exhibit 99.1 to this report.

### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) EXHIBITS.

| EXHIBIT NO.<br>----- | DESCRIPTION<br>-----                                          |
|----------------------|---------------------------------------------------------------|
| 99.1                 | Press Release of Enzo Biochem, Inc., dated December 11, 2006. |

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: December 11, 2006

By: /S/ ELAZAR RABBANI

-----  
Dr. Elazar Rabbani  
Chairman of the Board and Chief  
Executive Officer

### EXHIBIT INDEX

| EXHIBIT NO.<br>----- | DESCRIPTION<br>----- |
|----------------------|----------------------|
|----------------------|----------------------|

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

99.1

Press Release of Enzo Biochem, Inc., dated December 11, 2006.